BioInvent International AB Cash Flow Conversion Efficiency
BioInvent International AB cash flow conversion efficiency. Based on the latest financial reports, BioInvent International AB (BINV) has a cash flow conversion efficiency ratio of 0.082x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr66.78 Million ≈ $7.19 Million USD) by net assets (Skr810.74 Million ≈ $87.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BioInvent International AB (2002–2024)
Cash flow conversion efficiency of BioInvent International AB from 2002 to 2024. This chart illustrates how BioInvent International AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BioInvent International AB share price for real-time trading data and today's change.
BioInvent International AB Cash Flow Conversion Ratio Explained
BioInvent International AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BioInvent International AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioInvent International AB ranked by their cash flow conversion efficiency. Also see market cap of BioInvent International AB for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wonpoong Corporation
KQ:008370
|
0.052x |
|
Berlian Laju Tanker Tbk PT
JK:BLTA
|
0.052x |
|
Rosebank Industries PLC
LSE:ROSE
|
0.000x |
|
Nandan Denim Limited
NSE:NDL
|
0.071x |
|
Dongwon Metal
KO:018500
|
0.143x |
|
Superlon Holdings Bhd
KLSE:7235
|
0.027x |
|
Tevogen Bio Holdings Inc.
NASDAQ:TVGN
|
0.338x |
|
Korea Steel Co Ltd
KO:007280
|
-0.016x |
Annual Cash Flow Conversion Efficiency for BioInvent International AB (2002–2024)
The table below shows the annual cash flow conversion efficiency of BioInvent International AB from 2002 to 2024. Review BioInvent International AB (BINV) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr885.82 Million ≈ $95.33 Million |
Skr-380.47 Million ≈ $-40.94 Million |
-0.430x | -64.64% |
| 2023-12-31 | Skr1.31 Billion ≈ $140.95 Million |
Skr-341.69 Million ≈ $-36.77 Million |
-0.261x | -916.36% |
| 2022-12-31 | Skr1.61 Billion ≈ $172.84 Million |
Skr-41.23 Million ≈ $-4.44 Million |
-0.026x | +85.73% |
| 2021-12-31 | Skr1.37 Billion ≈ $147.11 Million |
Skr-245.84 Million ≈ $-26.46 Million |
-0.180x | -113.52% |
| 2020-12-31 | Skr743.50 Million ≈ $80.01 Million |
Skr-62.62 Million ≈ $-6.74 Million |
-0.084x | +88.62% |
| 2019-12-31 | Skr169.44 Million ≈ $18.23 Million |
Skr-125.43 Million ≈ $-13.50 Million |
-0.740x | +54.13% |
| 2018-12-31 | Skr87.62 Million ≈ $9.43 Million |
Skr-141.39 Million ≈ $-15.22 Million |
-1.614x | -176.96% |
| 2017-12-31 | Skr130.22 Million ≈ $14.01 Million |
Skr-75.88 Million ≈ $-8.17 Million |
-0.583x | -86.35% |
| 2016-12-31 | Skr230.44 Million ≈ $24.80 Million |
Skr-72.05 Million ≈ $-7.75 Million |
-0.313x | +87.31% |
| 2015-12-31 | Skr29.45 Million ≈ $3.17 Million |
Skr-72.57 Million ≈ $-7.81 Million |
-2.464x | -69.91% |
| 2014-12-31 | Skr52.43 Million ≈ $5.64 Million |
Skr-76.03 Million ≈ $-8.18 Million |
-1.450x | -30.04% |
| 2013-12-31 | Skr49.01 Million ≈ $5.27 Million |
Skr-54.65 Million ≈ $-5.88 Million |
-1.115x | +68.83% |
| 2012-12-31 | Skr47.62 Million ≈ $5.13 Million |
Skr-170.38 Million ≈ $-18.34 Million |
-3.578x | -790.00% |
| 2011-12-31 | Skr137.95 Million ≈ $14.85 Million |
Skr-55.45 Million ≈ $-5.97 Million |
-0.402x | +74.66% |
| 2010-12-31 | Skr74.19 Million ≈ $7.98 Million |
Skr-117.70 Million ≈ $-12.67 Million |
-1.586x | +30.58% |
| 2009-12-31 | Skr55.63 Million ≈ $5.99 Million |
Skr-127.14 Million ≈ $-13.68 Million |
-2.285x | -1308.90% |
| 2008-12-31 | Skr231.30 Million ≈ $24.89 Million |
Skr43.73 Million ≈ $4.71 Million |
0.189x | +220.57% |
| 2007-12-31 | Skr214.12 Million ≈ $23.04 Million |
Skr12.63 Million ≈ $1.36 Million |
0.059x | +106.42% |
| 2006-12-31 | Skr110.15 Million ≈ $11.85 Million |
Skr-101.23 Million ≈ $-10.89 Million |
-0.919x | -90.80% |
| 2005-12-31 | Skr219.00 Million ≈ $23.57 Million |
Skr-105.48 Million ≈ $-11.35 Million |
-0.482x | -15.43% |
| 2004-12-31 | Skr212.68 Million ≈ $22.89 Million |
Skr-88.74 Million ≈ $-9.55 Million |
-0.417x | -92.09% |
| 2003-12-31 | Skr304.96 Million ≈ $32.82 Million |
Skr-66.25 Million ≈ $-7.13 Million |
-0.217x | -710.31% |
| 2002-12-31 | Skr394.25 Million ≈ $42.43 Million |
Skr-10.57 Million ≈ $-1.14 Million |
-0.027x | -- |
About BioInvent International AB
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an a… Read more